Our study, supporting the use of five approaches, including TMT, gene ontology (GO), Reactome, KEGG pathway, and molecular docking analyses, suggests that DEPs, Myh3, Eno2, and H4c11 may be three novel biomarkers or therapeutic targets for non-Hodgkin lymphoma. This evidence concerns the gene H4C11 and non-Hodgkin lymphoma.